Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Bernzott Capital Advisors

Bernzott Capital Advisors lessened its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 16.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,580 shares of the medical equipment provider's stock after selling 6,432 shares during the period. Bernzott Capital Advisors' holdings in Zimmer Biomet were worth $3,547,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ZBH. Geode Capital Management LLC boosted its holdings in shares of Zimmer Biomet by 2.6% during the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider's stock worth $524,942,000 after acquiring an additional 125,852 shares during the period. M&T Bank Corp increased its holdings in Zimmer Biomet by 48.4% in the 3rd quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider's stock valued at $2,884,000 after buying an additional 8,709 shares during the period. National Pension Service lifted its holdings in shares of Zimmer Biomet by 3.8% during the 3rd quarter. National Pension Service now owns 369,547 shares of the medical equipment provider's stock worth $39,893,000 after acquiring an additional 13,612 shares during the period. Peddock Capital Advisors LLC bought a new position in Zimmer Biomet in the fourth quarter valued at approximately $654,000. Finally, River Global Investors LLP raised its position in Zimmer Biomet by 31.3% during the third quarter. River Global Investors LLP now owns 21,084 shares of the medical equipment provider's stock valued at $2,276,000 after purchasing an additional 5,030 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ZBH shares. Wells Fargo & Company raised their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the company an "equal weight" rating in a report on Thursday, October 31st. BTIG Research reduced their target price on shares of Zimmer Biomet from $134.00 to $126.00 and set a "buy" rating on the stock in a report on Thursday, October 3rd. Barclays lowered their price objective on Zimmer Biomet from $125.00 to $118.00 and set an "underweight" rating for the company in a research report on Thursday, December 12th. Evercore ISI cut their price target on shares of Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating on the stock in a research report on Tuesday, October 1st. Finally, Raymond James lowered their price objective on shares of Zimmer Biomet from $128.00 to $123.00 and set an "outperform" rating for the company in a research note on Monday, October 14th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $123.33.

Zimmer Biomet Stock Up 0.7 %

Zimmer Biomet stock traded up $0.71 during trading hours on Friday, reaching $109.65. The stock had a trading volume of 1,097,072 shares, compared to its average volume of 1,619,107. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The company has a market cap of $21.83 billion, a price-to-earnings ratio of 20.85, a PEG ratio of 1.79 and a beta of 1.02. The business's 50 day moving average price is $107.81 and its 200-day moving average price is $107.97. Zimmer Biomet Holdings, Inc. has a 52 week low of $100.67 and a 52 week high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter last year, the company earned $1.65 earnings per share. The company's quarterly revenue was up 4.1% on a year-over-year basis. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.88%. Zimmer Biomet's dividend payout ratio is presently 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.